Letrozole (trade name Femera)

Views 1474
Download the GMI DOC on this Topic

Sign in to Purchase/Download Documents

Sign in / Register

Focus Your Research

Click any topic below to filter + focus research
19 Diseases Researched for Letrozole (trade name Femera)
NameACCKFocus
Drug-Induced Toxicity 432Locked
Breast Cancer330Locked
Musculoskeletal Abnormalities330Locked
Arthralgia110Locked
Arthritis110Locked
Bone Diseases110Locked
Breast Cancer: Recovery 110Locked
Children: Impaired Growth110Locked
HPA Axis Dysregulation110Locked
Insulin-like Growth Factor (IGF): Elevated110Locked
Myalgias110Locked
Osteoporosis110Locked
Polymyalgia Rheumatica110Locked
Prostatic Hyperplasia: Benign110Locked
Tendinitis110Locked
Birth Defects24Locked
Polycystic Ovary Syndrome24Locked
Prenatal Chemical Exposures24Locked
Abortion: Spontaneous12Locked
5 Adverse Pharmacological Actions Researched for Letrozole (trade name Femera)
NameACCKFocus
Carcinogenic110Locked
Endocrine Disruptor110Locked
Endocrine Disruptor: Pituitary110Locked
Embryotoxic24Locked
Teratogenic24Locked
Related Topics

Letrozole (trade name Femera) is a Sub of the following Topic

View the Evidence:
12 Abstracts with Letrozole (trade name Femera) Research

[+]

Arimidex therapy contributes in the decline of bone mineral density in early breast cancer patients.Jan 01, 2010

Pubmed Data : Bratisl Lek Listy. 2010;111(1):27-32. PMID: 20429308
Article Published Date : Jan 01, 2010
Study Type : Human Study
Additional Links
Diseases : Breast Cancer, Osteoporosis
Additional Keywords : Drug: Tamoxifen
Problem Substances : Arimidex, Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
[+]

Clinically relevant musculoskeletal symptoms develop in women treated with aromatase inhibitors, leading to treatment discontinuation in a substantial percentage of these patients.Sep 15, 2010

Pubmed Data : Cancer. 2010 Sep 15;116(18):4360-7. PMID: 20549827
Article Published Date : Sep 15, 2010
Study Type : Human Study
Additional Links
Diseases : Drug-Induced Toxicity , Musculoskeletal Abnormalities
Problem Substances : Exemestane, Letrozole (trade name Femera)
[+]

Letrozole decreases estrogen levels at 12 months but not 24 months, reduces bone density, does not reduce mammographic breast density at 12 months and increases IGF-1 (a known carcinogen) at 12 and 24 months in Apr 01, 2010

Pubmed Data : Breast Cancer Res Treat. 2010 Apr;120(2):427-35. Epub 2009 Dec 6. PMID: 19967558
Article Published Date : Apr 01, 2010
Study Type : Human Study
Additional Links
Diseases : Breast Cancer, Insulin-like Growth Factor (IGF): Elevated
Problem Substances : Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
Adverse Pharmacological Actions : Carcinogenic
[+]

Musculoskeletal complaints are exceedingly common (71.5%) in those receiving long-term (6 months or longer) aromatase inhibitor therapy.Feb 01, 2010

Pubmed Data : Breast Cancer Res Treat. 2010 Feb;120(1):127-34. Epub 2009 Dec 25. PMID: 20035381
Article Published Date : Feb 01, 2010
Study Type : Human Study
Additional Links
Diseases : Arthralgia, Arthritis, Breast Cancer, Drug-Induced Toxicity , Musculoskeletal Abnormalities, Myalgias, Polymyalgia Rheumatica, Tendinitis
Problem Substances : Arimidex, Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
[+]

Musculoskeletal pains in breast cancer patients under third generation AIs can be severe, debilitating and are associated with tenosynovial and joint changes.Jul 01, 2007

Pubmed Data : Breast Cancer Res Treat. 2007 Jul;104(1):87-91. Epub 2006 Oct 24. PMID: 17061044
Article Published Date : Jul 01, 2007
Study Type : Human Study
Additional Links
Diseases : Breast Cancer: Recovery , Musculoskeletal Abnormalities
Problem Substances : Aromatase Inhibitor Drugs, Exemestane, Letrozole (trade name Femera)
[+]

Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.Oct 01, 2010

Pubmed Data : J Endocrinol. 2010 Oct;207(1):27-34. Epub 2010 Jul 30. PMID: 20675302
Article Published Date : Oct 01, 2010
Study Type : Human Study
Additional Links
Diseases : Bone Diseases, Children: Impaired Growth, Drug-Induced Toxicity , Prostatic Hyperplasia: Benign
Problem Substances : Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
Adverse Pharmacological Actions : Endocrine Disruptor
[+]

The aromatase inhibitor letrozole has endocrine disruptive properties on hypothalamic-pituitary output in normal women.Feb 24, 2011

Pubmed Data : Fertil Steril. 2011 Feb 24. Epub 2011 Feb 24. PMID: 21353673
Article Published Date : Feb 24, 2011
Study Type : Human Study
Additional Links
Diseases : HPA Axis Dysregulation
Problem Substances : Letrozole (trade name Femera)
Adverse Pharmacological Actions : Endocrine Disruptor: Pituitary
[+]

The aromatase inhibitors anastrozole, letrozole and exemestane have been associated with skeletal complications, arthralgia, mucuoskeletal pain and sexual dysfunction.Feb 01, 2008

Pubmed Data : Ther Clin Risk Manag. 2008 Feb;4(1):189-204. PMID: 18728707
Article Published Date : Feb 01, 2008
Study Type : Human Study
Additional Links
Problem Substances : Arimidex, Aromatase Inhibitor Drugs, Exemestane, Letrozole (trade name Femera)
[+]

Gestational exposure to doses of letrozole that are equal to or lower than the daily recommended human dose has toxic effects on prenatal development in rats.Aug 01, 2008

Pubmed Data : Hum Reprod. 2008 Aug;23(8):1719-23. Epub 2008 May 15. PMID: 18487213
Article Published Date : Aug 01, 2008
Study Type : Animal Study
Additional Links
Diseases : Birth Defects, Drug-Induced Toxicity , Prenatal Chemical Exposures
Problem Substances : Letrozole (trade name Femera)
Adverse Pharmacological Actions : Embryotoxic, Teratogenic
[+]

Letrozole has a toxic effect on the embryos of rats. Nov 01, 2009

Pubmed Data : Hum Reprod. 2009 Nov;24(11):2688-92. Epub 2009 Jul 27. PMID: 19638353
Article Published Date : Nov 01, 2009
Study Type : Animal Study
Additional Links
Diseases : Abortion: Spontaneous, Birth Defects, Prenatal Chemical Exposures
Problem Substances : Letrozole (trade name Femera)
Adverse Pharmacological Actions : Embryotoxic, Teratogenic
[+]

Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole-induced polycystic ovary syndrome.May 09, 2023

Pubmed Data : Phytother Res. 2023 May 10. Epub 2023 May 10. PMID: 37165686
Article Published Date : May 09, 2023
Study Type : Animal Study
Additional Links
Substances : Naringenin
Diseases : Polycystic Ovary Syndrome
Problem Substances : Letrozole (trade name Femera)
[+]

Ocimum kilimandscharicum L. restores ovarian functions in letrozole-induced polycystic ovary syndrome.Jul 07, 2019

Pubmed Data : Life Sci. 2019 Jul 8:116640. Epub 2019 Jul 8. PMID: 31295470
Article Published Date : Jul 07, 2019
Study Type : Animal Study
Additional Links
Substances : African Basil
Diseases : Polycystic Ovary Syndrome
Pharmacological Actions : Insulin Sensitizers
Problem Substances : Letrozole (trade name Femera)

Print Options

Some features are currently member only features. If you are already a member, please login. Otherwise, click here to become a member.
  • Printer-friendly version

Connect with GreenMedInfo

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.